Wednesday, July 8, 2026

Patent intelligence · US

US 12304901

Selective ligands for tau aggregates

granted A61KA61K31/4545A61K51/0455A61P
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 19
Applicant portfolio 86
Patent details — US 12304901
Jurisdiction
US
Status
granted
Grant date
May 20, 2025
Expiration
May 15, 2045
Applicant
Sentonix, Inc.
Claims
18
CPC classes
A61K, A61K31/4545, A61K51/0455, A61P
View on Google Patents ↗

Quick answer

US 12304901 (Selective ligands for tau aggregates) is held by Sentonix, Inc.. Status: granted. Granted May 20, 2025. Expires May 15, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Sentonix, Inc.
Grant date
Expiration
Claims
18
CPC classes
A61K, A61K31/4545, A61K51/0455, A61P, A61P25/28

More from Sentonix, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12383733

    Iontophoresis-based patch type medicine absorption device

    ROOTONIX Co., Ltd. · Expires Aug 7, 2045

    granted
  2. US 12365879

    Synthetic chimeric poxviruses

    TONIX PHARMA LIMITED · Expires Jul 17, 2045

    granted
  3. US 12156897

    Magnesium-containing oxytocin formulations and methods of use

    TONIX PHARMA LIMITED · Expires Nov 28, 2044

    granted
  4. US 12156864

    Analogs of cyclobenzaprine and amitryptilene

    TONIX PHARMACEUTICALS HOLDING CORP · Expires Nov 28, 2044

    granted
  5. US 12097183

    Pharmaceutical composition for treating migraine

    Tonix Medicines, Inc. · Expires Sep 19, 2044

    granted
  6. US 12090139

    Formulations comprising triptan compounds

    Tonix Medicines, Inc. · Expires Sep 12, 2044

    granted
  7. US 11998516

    Methods and compositions for treating depression using cyclobenzaprine

    TONIX PHARMA LIMITED · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 12304901?

US 12304901 (Selective ligands for tau aggregates) is held by Sentonix, Inc.. Status: granted. Granted May 20, 2025. Expires May 15, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12304901?

Sentonix, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.

When does US 12304901 expire?

Our index shows an expiration date of May 15, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.